ArticleThe Journal of surgical research2025
Surgical Considerations for Patients With De Novo Metastatic Breast Cancer Based on Prognostic Group.
Article in The Journal of surgical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
introductionAdvances in systemic therapy for de novo metastatic breast cancer (dnMBC) led to the development of a novel staging system (IVA-D), which stratifies patients into prognostic subgroups based on tumor characteristics and metastatic extent. Overall survival (OS) varies between subgroups; therefore, different treatment approaches may be considered. This study explores the association of surgery of the primary tumor with OS among prognostic subgroups.
methodsPatients with dnMBC (2010-2020) receiving systemic therapy were selected from the National Cancer Database (NCDB) and stratified by prognostic stage group (IVA-D). A landmark analysis was employed with OS defined as the time from diagnosis, plus 12 mo, to death due to any cause. Kaplan-Meier methods, log-rank tests, and adjusted Cox models evaluated OS differences and associations.
resultsAmong 42,824 patients, subgroups included IVA 7.3%, IVB 55.7%, IVC 27.4%, and IVD 9.5%. Surgery receipt varied by subgroups: IVA 34.5%, IVB 23.7%, IVC 21.5%, and IVD 29.8% (P < 0.001). After adjustment, surgery was associated with younger age, fewer comorbidities, and private insurance (all P < 0.05). Median OS varied: IVA 84.5 mo, IVB 49.4 mo, IVC 30.8 mo, and IVD 15.3 mo. Among those with IVA disease, surgery patients had better unadjusted 5-y OS (77.5% versus 49.7%, log rank P < 0.001). Despite lower absolute survival in advanced stages (IVB-D), surgery remained associated with significantly higher OS. Adjusted analysis confirmed surgery's association with improved OS (hazard ratio (HR) 0.60, 95% confidence interval (CI) 0.57-0.63).
conclusionsSurgery of the primary tumor may be associated with better survival for selected patients with dnMBC, and future prospective studies may consider exploring this association using prognostic subgroups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.